A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
CONTEXT: Tirzepatide, a dual glucose-dependent insulinotropic peptide/glucagon-like peptide 1 (GIP/GLP1) receptor agonist, was recently approved for type 2 diabetes and weight management. Alström syndrome (AS) is a rare, genetic, multisystemic disord…
OBJECTIVE: Tirzepatide, a long-acting, glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, reduced urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) decline in people with type…
Emerging clinical data support the paradoxical notion that glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) agonism and antagonism can provide additive weight loss when combined with a glucagon-like peptide 1 (GLP-1) receptor (GLP-1…
OBJECTIVE: Patients prescribed second-generation antipsychotics (SGA) are at risk of antipsychotic induced weight gain (AIWG). The objective was to estimate weight changes after prescription of incretin-based weight loss medications by category of ex…
IMPORTANCE: Patients who have undergone bariatric surgery have an elevated risk for alcohol use disorder (AUD). Incretin-based therapies (IBTs) may be associated with reward pathways in addition to weight loss. OBJECTIVE: To evaluate whether IBT afte…
Positive airway pressure therapy remains the gold standard treatment for obstructive sleep apnea (OSA), but challenges with adherence, acceptability, and side effects persist. Interest in pharmacological therapies has grown, culminating in the recent…
Metabolic dysfunction-associated steatohepatitis (MASH), the progressive inflammatory form of MASLD, is now a leading cause of chronic liver disease worldwide. Driven by obesity and type 2 diabetes, MASH significantly increases the risk of cirrhosis,…
Fifteen to forty% of patients experience recurrent weight gain (RWG) after metabolic bariatric surgery (MBS). Glucagon-like peptide receptor agonists (GLP-1 RAs) are effective treatments for obesity in nonsurgical patients. To assess the effects of s…
BACKGROUND: GLP-1 medicines (e.g. Semaglutide; Tirzepatide) are diabetes medicines that have recently been approved for weight loss purposes. These drugs are increasingly common, with many users accessing these medicines for off-label lifestyle-orien…
OBJECTIVE: Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) administration has been associated with neuroproliferative effects and modulatory effects in neuronal pathways. Herein, we conducted a comprehensive sy…
AIM: To evaluate whether tirzepatide use is associated with a reduced risk of new-onset heart failure (HF) in patients with obesity. METHODS: We conducted a retrospective cohort study using the TriNetX global database, identifying adults with obesity…
On June 26, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the personalized approach of tirzepatide («Tirzetta®») and semaglutide («Velgia Eco®») in patients with excess body weight, obesity, and type 2 diab…
OBJECTIVE: We assessed the impact of medical weight management (MWM; lifestyle modification ± obesity medications) on major adverse cardiovascular events (MACE) compared to metabolic and bariatric surgery (MBS) and usual care (UC). METHODS: We retros…
Therapeutic proteins and peptides have revolutionized modern biomedicine, but their oral delivery is limited by gastrointestinal degradation and barriers. Small extracellular vesicles (sEVs), which are resistant to biochemical degradation and capable…
OBJECTIVE: This systematic review aimed to assess the efficacy and safety of GLP-1 RAs in adults with obesity or overweight, by comparing different GLP-1 RAs, identifying the most effective agents, and evaluating adverse effects. METHODS: We systemat…
Type 2 diabetes mellitus (T2D) and cardiovascular disease (CVD) are not merely coexisting epidemics but co-evolving manifestations of a shared cardiometabolic continuum. Despite advances in glycemic, lipid, and blood pressure control, residual cardio…